- Published on
Clinical Toxicology — Rifampin (Rifampicin)
1. Overview
Rifampin, also known internationally as rifampicin, is a rifamycin-class antibiotic used primarily to treat tuberculosis and other selected bacterial infections.
Its clinical and toxicologic importance extends beyond direct drug poisoning because rifampin is a potent inducer of drug-metabolizing enzymes and transporters. It can substantially reduce the effectiveness of other medications, including hormonal contraceptives, anticoagulants, certain antiretrovirals, and immunosuppressants.
Three distinct toxicologic presentations must be recognized:
- Acute overdose: Nausea, vomiting, abdominal pain, lethargy, orange-red discoloration, and occasionally significant hepatic or cardiovascular injury.
- Treatment-associated liver injury: Hepatitis, cholestasis, or more severe hepatic dysfunction, particularly in susceptible patients or during combination tuberculosis therapy.
- Immune-mediated toxicity: Flu-like reactions, thrombocytopenia, hemolysis, acute kidney injury, and occasionally shock, especially following interrupted or intermittent treatment.
There is no specific antidote for isolated rifampin poisoning. Treatment consists of supportive care, appropriate laboratory monitoring, and management of complications.
Identification of combination products is essential because accompanying isoniazid can produce immediately life-threatening seizures and metabolic acidosis.
2. Forms and therapeutic uses
Available preparations
Rifampin is available in oral capsules, including 150 mg and 300 mg strengths, and intravenous formulations for selected indications.
Historical and current combination products include:
Rifamate: Rifampin 300 mg with isoniazid 150 mg per capsule.
Rifater: Rifampin 120 mg, isoniazid 50 mg, and pyrazinamide 300 mg per tablet.
Other fixed-dose tuberculosis combinations vary by country.
Tuberculosis
Rifampin is a cornerstone of treatment for drug-susceptible tuberculosis.
Usual adult dosing in conventional regimens is approximately 10 mg/kg once daily, up to 600 mg daily.
Pediatric regimens commonly use 10–20 mg/kg daily, up to 600 mg, although dosing depends on the treatment guideline and patient circumstances.
Rifampin must be used with other effective agents when treating active tuberculosis to reduce the risk of acquired drug resistance.
Contemporary guidelines include traditional six-month rifampin-based regimens and shorter regimens for eligible patients. Some four-month regimens use rifapentine rather than rifampin; these two drugs should not be confused.
Latent tuberculosis infection
Four months of daily rifampin is a recommended regimen for many patients with latent tuberculosis infection.
The choice depends on drug interactions, pregnancy, susceptibility of the source organism, and other factors.
Meningococcal chemoprophylaxis
Rifampin is used to prevent secondary meningococcal disease in qualifying close contacts.
The CDC regimen is:
- Adults: 600 mg orally every 12 hours for two days.
- Children aged one month or older: 10 mg/kg every 12 hours for two days, maximum 600 mg per dose.
- Infants younger than one month: 5 mg/kg every 12 hours for two days, with specialist discussion recommended.
Ceftriaxone and ciprofloxacin are other established options, although local fluoroquinolone resistance influences selection.
Rifampin prophylaxis is not the same as treatment of invasive meningococcal meningitis.
Other infections
Rifampin may be used in combination with other antibiotics for selected infections involving prosthetic material or particular bacterial pathogens.
It should not be added indiscriminately because resistance can develop rapidly when used improperly.
3. Mechanism of action and toxicokinetics
Antibacterial action
Rifampin binds to bacterial DNA-dependent RNA polymerase and inhibits RNA transcription.
This mechanism explains its antibacterial activity.
Absorption
Rifampin is generally well absorbed after oral administration.
Peak plasma concentrations commonly occur within approximately two to four hours.
Metabolism and elimination
Rifampin undergoes hepatic metabolism and biliary excretion, with enterohepatic recirculation.
Its metabolites and a smaller fraction of unchanged drug are also eliminated through the kidneys.
The elimination half-life is dose- and treatment-dependent.
Autoinduction
Repeated rifampin administration increases activity of enzymes involved in its own metabolism.
This can increase clearance during continuing treatment.
Drug interaction mechanism
Rifampin induces multiple pathways, including CYP3A4, CYP2C9, CYP2C19, several glucuronidation pathways, and transporters such as P-glycoprotein.
As a result, coadministered drugs may be cleared more rapidly or have altered exposure.
The full interaction effect takes time to develop and may persist after rifampin is discontinued.
Starting and stopping rifampin can both create clinically important drug interactions.
4. Toxic dose
A reliable minimum toxic or lethal dose has not been established.
The older threshold of 100 mg/kg is not a validated cutoff for clinically significant poisoning.
Published adult cases have described survival after ingestions of approximately 9–12 g and fatalities after approximately 14–60 g.
These observations cannot reliably predict an individual patient’s outcome.
Important modifying factors include:
- Previous liver disease.
- Alcohol-related liver injury.
- Concomitant hepatotoxic medications.
- Combination-product ingredients.
- Time to medical treatment.
- Age and other medical conditions.
A history of intermittent treatment or recent re-exposure is especially relevant to immune-mediated reactions.
5. Acute overdose manifestations
Gastrointestinal symptoms
Nausea, vomiting, abdominal pain, and diarrhea may occur shortly after ingestion.
Orange-red discoloration
Rifampin and its metabolites can discolor:
- Urine.
- Tears.
- Saliva.
- Sweat.
- Sputum.
- Feces.
- Skin.
The color may range from orange to reddish brown.
This discoloration is generally a predictable drug effect rather than evidence of organ injury.
Historical “red man syndrome”
Severe overdose has occasionally caused striking orange-red skin coloration, facial flushing, pruritus, and facial or periorbital swelling.
Older literature described this as rifampin-associated red man syndrome.
This terminology can be confused with vancomycin infusion reactions and is better avoided in contemporary clinical documentation.
Neurologic manifestations
Headache, dizziness, fatigue, confusion, and increasing lethargy may occur.
Seizures, coma, and profound neurologic impairment have been reported in severe cases.
Cardiovascular manifestations
Hypotension and tachycardia may occur.
Rare fatal overdoses have involved ventricular dysrhythmias and cardiac arrest.
Hepatic manifestations
Hepatomegaly, abdominal tenderness, elevated liver enzymes, hyperbilirubinemia, or jaundice may develop.
Severe hepatic injury is uncommon after isolated overdose but remains a major concern following substantial ingestion or in patients with underlying liver disease.
6. Treatment-associated hepatotoxicity
Rifampin can cause hepatocellular or cholestatic liver injury.
The presentation ranges from asymptomatic laboratory abnormalities to clinically apparent hepatitis and, rarely, severe hepatic dysfunction.
The risk of liver toxicity may increase when rifampin is combined with other hepatotoxic tuberculosis medications, particularly isoniazid or pyrazinamide.
Warning symptoms
Patients should seek immediate assessment for:
- Persistent nausea or vomiting.
- Marked loss of appetite.
- Unusual fatigue or weakness.
- Right-upper-quadrant pain.
- Dark urine.
- Pale stools.
- Yellow skin or eyes.
Laboratory findings
Possible abnormalities include increased AST, ALT, alkaline phosphatase, and bilirubin.
INR is important when severe hepatic injury is suspected.
Treatment interruption thresholds
Contemporary tuberculosis guidance generally recommends withholding potentially hepatotoxic tuberculosis medications when:
ALT or AST is at least three times the upper limit of normal with hepatitis symptoms, or
ALT or AST is at least five times the upper limit of normal without symptoms.
Significant bilirubin elevations or other serious clinical abnormalities also warrant urgent treatment reassessment.
The responsible regimen should be modified with tuberculosis-specialist input to avoid undertreatment and drug resistance.
A patient should not independently restart rifampin after suspected serious liver injury.
7. Immune-mediated reactions and interrupted therapy
Rifampin can cause unpredictable immunologic complications.
These are particularly associated with intermittent dosing or restarting treatment after a drug-free interval.
Flu-like syndrome
Patients may develop fever, chills, headache, muscle aches, joint pain, and malaise.
Severe cases may involve hypotension, wheezing, or shock.
Immune thrombocytopenia
Rifampin-dependent antibodies may cause rapid platelet destruction.
Clinical findings include bruising, petechiae, purpura, and bleeding.
Severe cases can produce life-threatening hemorrhage.
Hemolytic anemia
Immune-mediated red blood cell destruction may cause pallor, jaundice, dark urine, fatigue, and kidney injury.
Acute kidney injury
Rifampin-associated acute kidney injury may result from acute tubular injury, hemoglobin-associated pigment injury, or interstitial nephritis.
Patients may develop oliguria, hematuria, increasing creatinine, or other abnormalities.
Thrombotic microangiopathy
Rare cases of thrombotic microangiopathy have been reported.
The combination of anemia, thrombocytopenia, and kidney dysfunction requires urgent investigation.
Treatment
Immediately discontinue rifampin when a severe immune-mediated reaction is suspected.
Management includes supportive care, evaluation of hemolysis and kidney function, and appropriate hematology or nephrology consultation.
Patients with confirmed serious rifampin-induced immune reactions generally should not be rechallenged.
Restarting rifampin after a severe hypersensitivity reaction can be dangerous.
8. Major drug interactions
Rifampin is one of the most clinically important enzyme-inducing drugs.
Hormonal contraception
Rifampin can substantially reduce exposure to systemic hormonal contraceptives.
This increases the risk of contraceptive failure.
An appropriate nonhormonal or alternative contraceptive strategy is needed during treatment and for an interval after discontinuation, according to contraceptive guidance.
Anticoagulants
Rifampin can reduce the effectiveness of warfarin and certain direct oral anticoagulants.
Warfarin patients may require substantial dose changes and close INR monitoring.
For some direct oral anticoagulants, concurrent rifampin use should be avoided.
Antiretroviral medications
Rifampin interacts with numerous medications used to treat HIV.
Some combinations are contraindicated, while others require adjusted antiretroviral regimens.
Immunosuppressants
Concentrations of tacrolimus, cyclosporine, and other immunosuppressants may fall.
This can increase the risk of transplant rejection or loss of disease control.
Methadone
Rifampin may lower methadone exposure and precipitate opioid withdrawal.
Corticosteroids
Rifampin can increase glucocorticoid clearance.
Patients receiving steroid replacement may be at risk of adrenal insufficiency if replacement doses become inadequate.
Antifungals and other drugs
Clinically important interactions also occur with selected azole antifungals, antiepileptics, cardiovascular medications, and other treatments.
Clinical warning
A medication interaction review is essential whenever rifampin is prescribed, stopped, or restarted.
9. Diagnosis and investigations
Exposure history
Identify whether the patient ingested rifampin alone or a combination containing isoniazid, pyrazinamide, or another medication.
Record the estimated dose, timing, usual treatment schedule, recent missed doses, liver disease, alcohol consumption, and other medications.
Mild accidental exposure
Routine laboratory testing may be unnecessary after a confidently minor, isolated exposure in an asymptomatic patient.
Significant overdose
Investigations may include:
- Complete blood count with platelets.
- Electrolytes and glucose.
- Creatinine and kidney function.
- AST, ALT, alkaline phosphatase, and bilirubin.
- PT/INR.
- ECG.
- Blood gas and lactate when clinically indicated.
Suspected hemolysis
Obtain hemoglobin, reticulocyte count, bilirubin, LDH, haptoglobin, urinalysis, and direct antiglobulin testing as appropriate.
Suspected acute kidney injury
Monitor creatinine, electrolytes, urine output, and urinalysis.
Coingestants
For intentional or uncertain overdose, consider acetaminophen and salicylate testing.
Rifampin concentrations
Serum rifampin measurements are not routinely available or validated for management of acute overdose.
Clinical findings and organ-function testing remain more important.
10. Combination-product overdose
Isoniazid
This is the most important immediate combination-product concern.
A significant isoniazid overdose can produce:
- Recurrent generalized seizures.
- Severe high-anion-gap metabolic acidosis.
- Coma.
- Respiratory failure.
Intravenous pyridoxine is the specific antidotal treatment for isoniazid-associated seizures and toxicity.
Pyridoxine is generally administered in an amount corresponding to the estimated ingested isoniazid dose when known, according to a medical toxicology protocol.
An unknown-dose severe exposure requires empiric dosing under emergency toxicology guidance.
Pyrazinamide
Pyrazinamide adds potential gastrointestinal and hepatic toxicity.
Clinical implication
Do not assume that the severity of a Rifamate or Rifater overdose can be predicted from the rifampin dose alone.
11. Treatment of acute overdose
Initial measures
There is no specific rifampin antidote.
Assess airway, breathing, circulation, mental status, and possible coingestants.
Provide supportive care guided by the clinical findings.
Gastrointestinal decontamination
Do not induce vomiting.
Routine gastric lavage is not recommended, despite its continued description in some prescribing information.
A single dose of activated charcoal may be considered after a substantial recent ingestion when the airway is intact or protected.
The clinical benefit specifically for rifampin overdose has not been established.
Multiple-dose charcoal
Rifampin undergoes biliary excretion and enterohepatic recirculation.
However, routine multiple-dose activated charcoal is not supported by convincing clinical outcome evidence.
It should not be administered automatically simply because enterohepatic circulation occurs.
Gastrointestinal symptoms
Antiemetics and appropriate hydration may be used.
Hypotension
Treat significant dehydration with titrated isotonic crystalloid.
Persistent shock may require norepinephrine and intensive-care support.
Seizures
Benzodiazepines are first-line treatment for toxin-associated seizures.
When isoniazid coingestion is possible, administer pyridoxine promptly according to the relevant protocol.
Hepatic injury
Monitor liver enzymes, bilirubin, INR, glucose, and mental status.
Severe hepatic dysfunction warrants early hepatology assessment.
Acute liver failure may require liver-transplant-center involvement.
Hematologic and renal complications
Treat hemolysis, severe thrombocytopenia, kidney injury, and other immune-mediated conditions according to their specific complications.
Discontinue the suspected causative medication.
12. Extracorporeal treatment
Hemodialysis
Hemodialysis is not an established routine method for substantially enhancing rifampin elimination.
There is limited evidence supporting extracorporeal removal as a treatment for isolated rifampin overdose.
However, renal replacement therapy may be necessary for conventional indications, including severe acute kidney injury, refractory electrolyte abnormalities, or clinically important metabolic complications.
Important combination-product distinction
Hemodialysis may be considered in selected cases of severe isoniazid toxicity, particularly when conventional measures fail.
This does not establish dialysis as standard treatment for isolated rifampin poisoning.
Forced diuresis
Forced diuresis is not recommended routinely to enhance rifampin elimination.
Excessive fluid administration can cause complications without demonstrated benefit.
13. Monitoring, observation, and disposition
Minor isolated exposure
Some patients with clearly minor accidental ingestion may be managed after poison-center advice and appropriate observation.
Significant acute overdose
Monitor for gastrointestinal symptoms, altered consciousness, hemodynamic instability, liver injury, and other complications.
Laboratory monitoring
After substantial overdose or development of symptoms, repeat hepatic and renal testing according to severity and clinical evolution.
Liver injury may progress after initial symptoms improve.
Observation duration
A universal six-hour discharge rule is not reliable for all rifampin exposures.
A short observation period may be suitable for selected low-risk patients, but significant overdose, abnormal laboratory results, underlying liver disease, or combination-product ingestion requires more cautious assessment.
Hospital admission
Admission is appropriate for:
- Persistent vomiting or dehydration.
- Altered consciousness.
- Significant liver injury.
- Abnormal INR.
- Hemolysis or thrombocytopenia.
- Acute kidney injury.
- Significant hypotension.
- Seizures.
- Clinically important coingestant toxicity.
Intensive care
ICU admission is appropriate for seizures, coma, respiratory failure, shock, acute liver failure, or severe metabolic abnormalities.
Discharge
Discharge requires stable clinical findings, appropriate laboratory assessment, adequate observation, and an individualized follow-up plan.
Patients undergoing tuberculosis treatment require careful coordination before restarting or modifying therapy.
Intentional overdose also warrants appropriate mental health assessment.
14. Pregnancy and breastfeeding
Pregnancy
The older FDA pregnancy letter categories are obsolete.
Rifampin may be used during pregnancy when clinically indicated.
Untreated active tuberculosis poses substantial maternal and fetal risks and should not be left untreated because of pregnancy.
CDC guidance supports rifampin-containing regimens during pregnancy, with treatment selection based on the form of tuberculosis, coadministered drugs, and maternal circumstances.
Meningococcal prophylaxis in pregnancy
Although rifampin can be used for tuberculosis during pregnancy, ceftriaxone is generally recommended for meningococcal exposure prophylaxis in pregnant patients.
The preferred drug depends on the indication.
Breastfeeding
Rifampin is generally compatible with breastfeeding during recommended tuberculosis treatment.
Breastmilk concentrations are too low to treat tuberculosis in an infant but are not generally considered toxic.
Orange discoloration of breast milk may occur and is harmless.
15. Prevention and patient education
Adherence
Patients taking rifampin for tuberculosis should follow the prescribed regimen carefully.
Missed doses, interrupted treatment, or unapproved restarts can contribute to treatment failure, drug resistance, and certain immune-mediated reactions.
Drug interactions
Patients should inform clinicians and pharmacists about all prescription medications, over-the-counter products, and supplements.
Particular attention should be given to hormonal contraception, anticoagulants, HIV medications, methadone, and immunosuppressants.
Body-fluid discoloration
Orange or red discoloration of urine, tears, sweat, and saliva is expected.
Soft contact lenses may become permanently stained.
Expected orange coloration should be distinguished from brown urine associated with hepatitis or urine containing blood.
Hepatic warning symptoms
Patients should seek urgent medical advice for jaundice, persistent nausea, loss of appetite, abdominal pain, dark urine, or unusual fatigue.
Immune-reaction warning symptoms
Unexplained fever after restarting treatment, bruising, bleeding, reduced urination, or severe weakness requires prompt medical assessment.
16. Clinical pitfalls
Using 100 mg/kg as a definitive toxic-dose threshold. No reliable universal cutoff exists.
Assuming orange-red urine means kidney injury. Discoloration is a predictable drug effect, although hematuria and hemolysis must be considered when other symptoms occur.
Treating all rifampin toxicity as ordinary dose-dependent poisoning. Serious immune reactions can develop after therapeutic re-exposure.
Overlooking isoniazid in combination products. Pyridoxine may be urgently required for seizures.
Ignoring drug interactions after rifampin is stopped. Enzyme induction does not disappear immediately.
Assuming rifampin is contraindicated during pregnancy. It remains important in tuberculosis treatment.
Applying tuberculosis pregnancy guidance to meningococcal prophylaxis without distinction. Ceftriaxone is usually favored for prophylaxis during pregnancy.
Performing routine gastric lavage or inducing vomiting. These historical treatments should be removed.
Administering multiple-dose charcoal automatically. Clinical benefit has not been established.
Using forced diuresis as routine treatment. It has no established role.
Assuming every overdose is safe for discharge after six hours. Combination products, liver injury, and immune complications require individualized assessment.
Restarting rifampin after serious thrombocytopenia or hemolysis. Re-exposure may cause a severe or fatal reaction.
Key clinical conclusions
Rifampin is an essential antimicrobial whose toxicology includes acute overdose, treatment-associated liver injury, serious drug interactions, and immune-mediated reactions during interrupted or restarted treatment.
Most mild isolated ingestions resolve with supportive care, but severe poisoning can produce hepatic injury, altered consciousness, shock, or other systemic complications.
The most dangerous diagnostic errors are failure to identify isoniazid-containing combination products, failure to recognize immune-mediated hemolysis or kidney injury, and failure to account for major medication interactions.
There is no specific rifampin antidote. Treatment is supportive and guided by clinical findings, with specialist management of hepatic failure, hematologic reactions, renal injury, and significant coingestant toxicity.